Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 23:8:7-11.
doi: 10.2147/PTT.S161437. eCollection 2017.

Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis

Florian Anzengruber  1   2 , Adhideb Ghosh  1   2   3 , Julia-Tatjana Maul  1   2 , Mathias Drach  1   2 , Alexander A Navarini  1   2   3
Affiliations

Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis

Florian Anzengruber et al. Psoriasis (Auckl). .

Abstract

Purpose: Several studies have suggested that an HLA-Cw6+ allele can predict an improved outcome of treatment in psoriasis patients. The aim of the study was to assess whether the published association between HLA-Cw6 allele carriers and response to ustekinumab has the potential to impact treatment decisions.

Patients and methods: Differences in Psoriasis Activity and Severity Index 50, 75, and 90; Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe psoriasis under treatment with ustekinumab were included in our study.

Results: There was no difference between the two groups with respect to Psoriasis Activity and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or Dermatology Life Quality Index.

Conclusion: In our retrospectively analyzed cohort, we could not detect the previously reported better response in HLA-Cw6+ vs. HLA-Cw6- patients.

Keywords: Cw6; HLA-Cw6; genetic variations; human leukocyte antigen; ustekinumab.

PubMed Disclaimer

Conflict of interest statement

Disclosure AAN is funded by the Promedica and Bruno - Bloch Foundation. He is on the advisory board of Janssen, AbbVie, Novartis, Celgene, MSD, Pfizer. FA is funded by Hochspezialisierte Medizin 2 from the canton of Zurich; he is also funded by Forschungskredit of the University of Zurich. FA received honoraria from AbbVie, Novartis, Celgene and Eli Lilly. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
PASI. Notes: As previously reported, patients with HLA-Cw6+ had a higher PASI at the start, but it was not significantly reduced after 4 months compared to the control group of HLA-Cw6– patients. Abbreviation: PASI, Psoriasis Activity and Severity Index.
Figure 2
Figure 2
NAPSI. Notes: The NAPSI even increased in the HLA-Cw6+ group, which is most likely due to the small number of participants, not to the ineffectiveness of secukinumab. Abbreviation: NAPSI, Nail Psoriasis Severity Index.
Figure 3
Figure 3
DLQI. Notes: Life quality was better in both groups after 4 months of treatment. A larger decrease in DLQI was seen among patients in the HLA-Cw6+ group. Abbreviation: DLQI, Dermatology Life Quality Index.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. O’Rielly DD, Rahman P. Genetics of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2014;28(5):673–685. - PubMed
    1. Nair RP, Stuart P, Henseler T, et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet. 2000;66(6):1833–1844. - PMC - PubMed
    1. Duffin KC, Woodcock J, Krueger GG. Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol Ther. 2010;23(2):101–113. - PubMed
    1. Mabuchi T, Ota T, Manabe Y, et al. HLA-C*12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese. J Dermatol. 2014;41(8):697–704. - PubMed
    1. Ruiz-Romeu E, Ferran M, Sagrista M, et al. Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis. J Allergy Clin Immunol. 2016;138(2):491–499.e496. - PubMed